Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 8/20 | 0.37 |
| ▸ | DRD5 | P21918 | 8/20 | 0.37 |
| ▸ | DRD2 | P14416 | 7/20 | 0.37 |
| ▸ | DRD3 | P35462 | 6/20 | 0.37 |
| ▸ | DRD4 | P21917 | 6/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10246508 | 0.78 | MAOA (0.41) | CYP1A2DRD1DRD5DRD2DRD3 | |
| SCHEMBL15045824 | 0.78 | MAOA (0.41) | CYP1A2DRD1DRD5DRD2DRD3 | |
| SCHEMBL6612719 | 0.77 | DRD2 (0.41) | DRD1DRD5DRD2DRD3ALOX15 | |
| SCHEMBL6612716 | 0.77 | DRD2 (0.41) | DRD1DRD5DRD2DRD3ALOX15 | |
| Hydrochloric Acid SCHEMBL11399645 | 0.74 | IDO1 (0.40) | CYP1A2DRD1DRD5DRD2DRD3 | |
| SCHEMBL12690128 | 0.72 | CYP1A2 (0.43) | CYP1A2DRD1DRD5DRD2DRD3 | |
| SCHEMBL13167844 | 0.71 | MAOA (0.45) | CYP1A2DRD1DRD3PTGS2HSD17B10 | |
| SCHEMBL4285081 | 0.71 | CYP1A2 (0.48) | CYP1A2DRD1DRD5DRD2DRD3 | |
| SCHEMBL17122841 | 0.70 | DRD2 (0.45) | DRD1DRD5DRD2DRD3DRD4 | |
| SCHEMBL12757011 | 0.67 | GAA (0.47) | DRD2MAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673932-B2 | Oxime substituted imidazo-containing compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-03-18 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-0711271-B1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-07 | — | — | EP | disclosed |
| EP-0711271-A1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-05-15 | — | — | EP | disclosed |
| WO-1995004027-A1 | AMINOINDANES AND RELATED COMPOUNDS USEFUL AS CALCIUM-CHANNEL ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | CYP1A2 303/4885DRD1 4069/4885DRD5 3913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.